What is N-Acetyl Epitalon?
N-Acetyl Epitalon — also written as N-Acetyl Epithalon — is a chemically modified variant of the tetrapeptide Epitalon (Ala-Glu-Asp-Gly), produced by adding an acetyl group (-COCH3) to the free alpha-amino group at the peptide’s N-terminus. This acetylation is a deliberate pharmaceutical modification designed to address specific pharmacological limitations of the parent compound and, according to the research literature, may enhance both stability and cellular bioavailability while preserving the core biological activities that have made Epitalon one of the most studied synthetic anti-aging peptides in existence.
Epitalon itself has a history stretching back to the work of Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology in the Soviet Union and later Russia, beginning in the late 1980s. Khavinson’s group isolated regulatory peptides from various organs and tissues, identifying short peptide sequences — called cytomedins or bioregulatory peptides — that appeared to normalize gene expression and cellular function in aging tissue. The tetrapeptide Ala-Glu-Asp-Gly was isolated from the bovine pineal gland extract (epithalamin) and named “Epitalon” for its epithalamic origin. Subsequent research over several decades has characterized Epitalon’s effects on telomerase activity, circadian rhythms, antioxidant defense, and longevity in multiple species.
The specific improvement offered by N-acetylation at the N-terminus is twofold. First, it blocks the free amino group that is the primary site of attack for aminopeptidases — enzymes in serum and tissues that cleave peptide bonds from the N-terminal end. By capping this group with an acetyl moiety, the peptide’s resistance to aminopeptidase degradation is substantially improved, translating to a longer effective half-life in biological fluids. Second, N-acetylation increases the lipophilicity of the N-terminal region of the peptide, which can enhance passive membrane permeability and potentially improve cellular uptake compared to the charged free amino form. These are well-established principles of medicinal chemistry applied to peptide optimization, and N-acetylation is used with many bioactive peptides for the same reasons.
From a research perspective, N-Acetyl Epitalon is studied as a potentially more potent and durable form of Epitalon — one that may achieve equivalent or greater biological effects with less frequent dosing due to its improved pharmacokinetic profile. The compound has attracted interest in the longevity research community due to Epitalon’s well-documented effects on telomerase activity and its promising results in aging animal studies. Explore related longevity peptides in our Peptide Database.
Research Benefits of N-Acetyl Epitalon
- Enhanced proteolytic stability: N-terminal acetylation blocks the primary site of aminopeptidase attack, substantially extending the half-life of the peptide in serum and biological fluids compared to standard Epitalon — the core pharmacological rationale for this modification.
- Telomerase activation and telomere maintenance: Like the parent compound, N-Acetyl Epitalon is proposed to activate human telomerase reverse transcriptase (hTERT) expression, enabling cells that have entered replicative senescence due to telomere shortening to restore functional telomere length.
- Potential for less frequent dosing: Improved stability in biological fluids suggests that the same biological effects may be achievable with fewer administrations compared to standard Epitalon, with implications for convenience and possibly for safety profile in chronic research applications.
- Pinealocyte function restoration and melatonin normalization: Both Epitalon and N-Acetyl Epitalon appear to restore pineal gland function in aged animals, normalizing blunted melatonin secretion and improving circadian rhythm integrity — with downstream effects on sleep, antioxidant status, and hormonal regulation.
- Improved cellular uptake potential: The lipophilicity increase from N-acetylation may enhance passive membrane penetration compared to the parent peptide, potentially improving intracellular delivery and nuclear access required for hTERT gene activation.
- Antioxidant system enhancement: Epitalon research has documented upregulation of antioxidant enzymes including superoxide dismutase (SOD) and catalase, and reduction of lipid peroxidation markers — effects attributed to both direct antioxidant activity and indirect effects through pineal and circadian function restoration.
- Circadian rhythm normalization: Through restoration of pineal melatonin output and possibly through direct effects on circadian gene expression, Epitalon-class compounds appear to normalize the disrupted circadian rhythms characteristic of aging, with potential benefits for metabolic regulation, immune function, and cellular repair programs that are circadian-gated.
- Longevity research applications: In animal studies, Epitalon treatment has been associated with increased maximum lifespan in both invertebrate and vertebrate models, and reduced spontaneous tumor incidence in rodent studies — findings that provide the biological context for the anti-aging research interest in this compound class.
How N-Acetyl Epitalon Works
hTERT Telomerase Activation and Telomere Length Maintenance
The most mechanistically characterized effect of Epitalon — and by extension N-Acetyl Epitalon — is its ability to activate expression of human telomerase reverse transcriptase (hTERT), the catalytic subunit of the telomerase enzyme. Understanding this mechanism requires brief context about telomere biology. Telomeres are repetitive DNA sequences (TTAGGG in humans) that cap the ends of chromosomes, protecting them from end-to-end fusion and degradation. Each round of DNA replication fails to fully copy the very ends of chromosomes — a consequence of the end-replication problem — so telomeres shorten progressively with each cell division. When telomeres reach a critically short length, the cell enters replicative senescence (permanent cell cycle arrest) or, if checkpoint mechanisms fail, genome instability. Telomerase, by adding new TTAGGG repeats to telomere ends, can counteract this shortening and extend replicative lifespan. Telomerase expression is active in stem cells, germ cells, and most cancer cells, but is largely silenced in most differentiated somatic cells — which is why somatic cells have a finite replicative lifespan.
Research by Khavinson and colleagues, confirmed by subsequent independent work, showed that Epitalon treatment of human fetal fibroblasts that had reached replicative crisis (near-senescent state) stimulated hTERT expression as measured by RT-PCR and enzyme activity assays. Treated cells continued to divide beyond the number of doublings observed in controls, with maintained telomere lengths. The molecular mechanism by which a four-amino acid peptide activates hTERT transcription is not fully characterized, but evidence points toward effects on chromatin structure in the hTERT promoter region — potentially involving histone modification or interactions with epigenetic regulatory proteins that control hTERT gene accessibility. N-Acetyl Epitalon is proposed to work through the same mechanism as Epitalon at this level, with the acetyl modification primarily affecting pharmacokinetics rather than fundamental mechanism of action at the molecular target.
Improved Peptidase Resistance from N-Terminal Acetylation
The pharmacological rationale for N-terminal acetylation is firmly grounded in biochemistry. Aminopeptidases are ubiquitous enzymes present in blood plasma, on cell surfaces, and intracellularly that sequentially cleave amino acids from the free N-terminus of peptides. For the standard Epitalon tetrapeptide (Ala-Glu-Asp-Gly), the free alpha-amino group at the N-terminal alanine provides a substrate recognition site for these enzymes. In plasma, aminopeptidase activity is substantial — small peptides with free N-termini have half-lives measured in minutes to low tens of minutes following intravenous or subcutaneous injection. By covalently attaching an acetyl group to block the free amino group, the N-Acetyl modification prevents aminopeptidase recognition at this end of the molecule. The result is a peptide that resists degradation from the N-terminus, forcing any proteolytic attack to occur at internal peptide bonds where enzyme recognition is less favorable for such a short peptide. The predicted and empirically supported consequence is a meaningfully longer biological half-life — allowing the compound to persist in circulation and tissues for a longer period after administration. For a four-amino acid peptide that is already at the lower size limit for practical drug-like behavior, every increment of stability improvement potentially translates to more reliable and reproducible biological activity.
Pinealocyte Function Restoration and Circadian Rhythm Normalization
The pineal gland is a small neuroendocrine structure that synthesizes and releases melatonin in a circadian pattern — high at night, low during the day — serving as the body’s primary circadian timing signal. Melatonin’s roles extend well beyond sleep regulation: it is a potent antioxidant, it modulates immune function, it has anti-tumor properties demonstrated in numerous animal and in vitro studies, and it acts on receptors throughout the body to synchronize peripheral circadian clocks with the central pacemaker in the suprachiasmatic nucleus. With aging, pineal gland function declines — pinealocytes (the secretory cells of the pineal) reduce in number and activity, melatonin secretion diminishes, and the circadian amplitude of the melatonin rhythm flattens. This melatonin decline contributes to the sleep disruption, immune senescence, increased oxidative stress, and hormonal dysregulation characteristic of aging. Epitalon was originally derived from pineal gland extracts, and its bioregulatory peptide character is consistent with a mechanism involving restoration of normal pinealocyte gene expression and secretory activity. Animal studies have shown that Epitalon treatment restores blunted nocturnal melatonin peaks in aged animals, normalizes circadian rhythm disruptions, and improves downstream markers including antioxidant enzyme activity. N-Acetyl Epitalon is proposed to act through the same pathway, potentially with greater efficiency due to improved delivery to pinealocyte cells resulting from enhanced cellular uptake and extended biological half-life.
Research Findings
Comparison to Standard Epitalon: Stability and Potency
The direct pharmacological comparison between N-Acetyl Epitalon and standard Epitalon forms the foundational rationale for the N-acetylated variant. Published work characterizing the stability difference has shown that N-acetylation produces meaningful protection from plasma aminopeptidases in vitro — when incubated with human or rat plasma, the N-acetylated form degrades substantially more slowly than the parent peptide, with half-life differences of several-fold reported in comparative stability assays. For a compound used at microgram quantities, this stability advantage could translate clinically to either lower effective doses (if comparable biological effect can be achieved with lower total exposure) or less frequent dosing (if similar plasma concentrations can be maintained with fewer injections). Biological activity comparison between the two forms in cell-based assays shows that N-Acetyl Epitalon retains the telomerase-activating and antioxidant-enhancing properties of the parent, with some studies reporting comparable or slightly enhanced potency. The improved lipophilicity may contribute to enhanced cellular uptake, though this has not been rigorously quantified across multiple cell types in published literature. These comparisons remain an area where additional rigorous head-to-head research would strengthen the evidence base for preferring the N-acetylated form.
Telomere Maintenance and Cellular Aging Research
Khavinson’s landmark work showing that Epitalon could activate telomerase in human fibroblasts and extend their replicative lifespan was published in 2003 and has been cited extensively in the longevity research literature. Subsequent work extended these findings to additional cell types, showing telomerase activation in human embryonic kidney cells and in immune cells. The implications for understanding cellular aging are significant: if a small, chemically simple peptide can reactivate a gene that is epigenetically silenced in most somatic cells and thereby restore replicative capacity to cells approaching senescence, this represents a novel mechanism for addressing one of the foundational biological processes of aging. However, the relationship between telomere length, cellular senescence, and organismal aging is complex — cellular senescence is not merely a passive consequence of telomere erosion but serves important tumor-suppressive and wound-healing functions, meaning that any intervention that broadly restores replicative capacity carries theoretical cancer risk considerations that must be weighed carefully. The animal longevity data for Epitalon — including studies showing increased maximum lifespan in Drosophila, rats, and mice — provide important context for interpreting the cellular data, suggesting that the compound’s overall biological effects in aging organisms may be net beneficial despite the theoretical complexity.
Circadian Rhythm and Sleep Research
The connection between Epitalon and circadian biology, mediated through pineal gland restoration, has been explored in both animal models and limited human studies. In aged Wistar rats with disrupted circadian locomotor activity rhythms, Epitalon treatment restored circadian amplitude and improved the regularity of the activity-rest cycle. These effects were accompanied by normalized nocturnal melatonin secretion, suggesting that the behavioral circadian improvements reflected genuine restoration of the pineal melatonin signal rather than direct CNS effects on the circadian clock. The clinical relevance of circadian normalization extends beyond sleep quality — disrupted circadian rhythms (chronodisruption) are associated with increased risk of metabolic syndrome, cardiovascular disease, immune dysfunction, and cancer. Normalizing melatonin secretion and circadian amplitude may therefore have broad health implications beyond simply improving sleep. N-Acetyl Epitalon is proposed to offer this same circadian normalization with potentially better consistency of effect due to its improved pharmacokinetic stability — though direct comparison studies in circadian disruption models have not been published to the same extent as the telomere and longevity literature.
Antioxidant Defense Enhancement
Multiple animal studies have shown that Epitalon treatment increases activity of key antioxidant enzymes including superoxide dismutase (SOD) and catalase, and reduces markers of oxidative damage including malondialdehyde (a lipid peroxidation marker). These effects have been observed in multiple tissues including liver, kidney, brain, and heart. The mechanism through which a tetrapeptide influences antioxidant enzyme expression is likely indirect — mediated through the peptide’s effects on pineal melatonin (melatonin directly upregulates antioxidant enzyme expression and is a direct free radical scavenger), through effects on redox-sensitive transcription factors, and possibly through direct epigenetic effects on antioxidant gene promoters if the telomere/chromatin effects of Epitalon extend to these targets. The antioxidant effects are particularly well documented in the context of Epitalon’s oncostatic properties — reduced oxidative stress is one mechanism by which the compound may reduce spontaneous tumor formation in aged animals. N-Acetyl Epitalon’s improved stability is predicted to produce more consistent antioxidant enhancement, though head-to-head comparisons of antioxidant enzyme induction between the two forms are limited in the published literature.
Potential for Reduced Dosing Frequency in Research Protocols
One practical implication of N-Acetyl Epitalon’s improved stability that deserves specific discussion is the potential for less frequent administration in chronic research protocols. Standard Epitalon research protocols — particularly those based on the original Khavinson clinical work — have used daily injection schedules for periods of 10-20 days, repeated every 3-6 months. This schedule was empirically derived from clinical observation rather than formal pharmacokinetic optimization, and it may reflect the short half-life of standard Epitalon rather than an inherent requirement of the biology. If N-Acetyl Epitalon maintains comparable plasma concentrations for longer periods after injection, the same biological outcomes might theoretically be achievable with every-other-day, twice-weekly, or even weekly dosing schedules. This is an area where formal pharmacokinetic studies comparing the two forms — measuring area under the curve, peak concentrations, and trough concentrations with different dosing intervals — would provide the evidence needed to rationally optimize N-Acetyl Epitalon protocols. As of current published literature, specific comparative pharmacokinetic data for N-Acetyl Epitalon versus standard Epitalon in vivo is limited, making exact dosing interval recommendations speculative pending such studies.
Dosage and Administration
Standard Epitalon Protocols as Reference Baseline
Since N-Acetyl Epitalon is a modified form of Epitalon, published Epitalon dosing protocols serve as the primary reference baseline. Human clinical research using standard Epitalon has most commonly employed daily doses of 5-10mg administered by subcutaneous injection, over 10-20 consecutive days, with courses repeated at 3-6 month intervals. Animal studies have used lower weight-adjusted doses reflecting interspecies pharmacokinetic differences. Some published protocols describe subcutaneous, intranasal, or intravenous administration. Because N-Acetyl Epitalon has improved stability, the theoretical expectation would be that equivalent biological effects are achievable with either the same dose administered less frequently, or a lower dose on the same schedule. Without formal comparative pharmacokinetic and pharmacodynamic studies, precise adjustments from standard Epitalon protocols to N-Acetyl Epitalon protocols involve extrapolation rather than direct evidence. For reconstitution calculations and concentration planning, use our Peptide Calculators.
Reconstitution and Storage
N-Acetyl Epitalon is supplied as a lyophilized powder and is typically reconstituted in bacteriostatic water, sterile saline, or sterile water at concentrations of 1-5mg/mL depending on the intended dose. The acetyl modification improves the compound’s stability in solution compared to standard Epitalon — reconstituted N-Acetyl Epitalon can be stored at 4°C for longer periods without significant degradation, and lyophilized material stored at -20°C or colder has excellent long-term stability. The peptide is soluble in aqueous solutions at typical research concentrations, and no organic co-solvent is required for reconstitution. Because of its small size and relatively simple structure, the compound is less susceptible to degradation from mechanical handling (agitation, freeze-thaw) than large proteins, but good handling practices — slow thawing, gentle mixing, protection from UV light — remain appropriate.
Routes of Administration Used in Research
Subcutaneous injection is the most commonly described route in published clinical and animal research for Epitalon and its variants, and it is expected to be the primary route for N-Acetyl Epitalon research as well. The subcutaneous route provides reasonable bioavailability for small peptides with good aqueous solubility. Intranasal administration has been explored for some Epitalon research due to the theoretical advantage of bypassing first-pass degradation and potentially achieving CNS access directly through olfactory pathways — relevant for the pineal gland effects of the compound. Intravenous administration has been used in some clinical protocols and provides the highest and most immediate bioavailability but requires more careful preparation and administration conditions. The improved stability of N-Acetyl Epitalon may make subcutaneous administration even more effective relative to standard Epitalon, as the longer half-life reduces the proportion of the dose lost to pre-absorption degradation at the injection site.
Cycling and Protocol Duration
The empirical protocol tradition for Epitalon has favored cycled administration — defined courses of 10-20 days followed by treatment-free intervals of months. This approach reflects the biological rationale that the compound’s primary effects (telomere restoration, pineal function improvement, epigenetic normalization) may not require continuous exposure but rather periodic reinforcement of biological processes that, once reactivated, can maintain themselves for extended periods. Whether N-Acetyl Epitalon’s improved stability changes the optimal cycling approach is an open research question. The possibility of fewer injections per cycle (due to extended half-life), longer intervals between cycles (if the biological effects are more durable), or lower total doses per cycle (if higher effective tissue concentrations are achieved) all represent areas where research comparing standard and N-acetylated forms under defined conditions would add significant value. Our AI Coach can provide updated guidance on current protocol approaches as the literature evolves.
Safety and Side Effects
Tolerability Profile of Epitalon and Expected Extension to N-Acetyl Form
The parent compound Epitalon has been studied in clinical contexts over several decades, primarily through the work of Khavinson’s group, and the safety record across these studies has been notably favorable. No significant adverse effects attributable to Epitalon at typical research doses have been reported in the published clinical literature — a finding consistent with the peptide’s natural origin (it is derived from an endogenous pineal extract) and its small size (which reduces immunogenicity risks). N-Acetyl Epitalon is expected to share this favorable tolerability profile, with the structural modification being limited to the N-terminal cap and not affecting the core tetrapeptide sequence. Local injection site reactions (transient redness, mild discomfort) are the most commonly noted observation with subcutaneous peptide injections of any kind and are not specific to this compound. Anti-peptide antibody formation is theoretically possible with repeated administration but has not been a prominent concern in the Epitalon clinical literature.
Telomerase Activation and Theoretical Oncological Considerations
The most significant theoretical safety concern with any telomerase-activating compound is the potential for promoting malignant cell growth. Telomerase is reactivated in approximately 85-90% of cancers, where it provides immortality to tumor cells by preventing telomere-mediated senescence. An agent that activates hTERT expression could theoretically do the same in pre-malignant cells or could accelerate existing malignant processes by reducing telomere-mediated growth constraints. This concern has been explicitly addressed in the Epitalon literature: rather than promoting tumor formation, the published animal data shows reduced spontaneous tumor incidence in aged animals treated with Epitalon. The explanation may involve the compound’s overall effects on cellular homeostasis — including antioxidant enhancement, circadian normalization, and immune function restoration — which could collectively reduce the mutational and microenvironmental factors that promote carcinogenesis. Nevertheless, the theoretical concern is legitimate enough that research protocols with this compound should include monitoring of relevant markers in chronic administration studies, and the compound should not be used in individuals with active malignancy or very high cancer risk without careful research design consideration.
Long-Term Safety and Research Gaps
The longest-duration human data for standard Epitalon comes from studies spanning multiple years with annual or semi-annual treatment cycles. These long-term data, while not from large randomized controlled trials by contemporary standards, do not reveal cumulative toxicity or delayed adverse effects. The transition to N-Acetyl Epitalon introduces a structural modification that has not been as extensively studied over long timeframes. N-acetylation is a common and generally well-tolerated modification — it is present in many naturally occurring proteins (N-terminal acetylation is one of the most common protein modifications in the human proteome) — but the specific long-term safety of N-Acetyl Epitalon as a pharmaceutical compound requires data that the current literature does not fully provide. Ongoing research and careful monitoring in research contexts are appropriate until a more complete safety picture emerges for the modified compound specifically.
Frequently Asked Questions
They share the same four-amino acid core sequence (Ala-Glu-Asp-Gly), but N-Acetyl Epitalon has an acetyl group (-COCH3) covalently attached to the free amino group at the N-terminal alanine residue. This modification is the only structural difference. The practical consequence is improved stability against aminopeptidase enzymes in biological fluids, which is predicted to extend the active half-life of the compound and potentially improve cellular uptake due to slightly increased lipophilicity. The biological targets and mechanisms of action are considered to be the same — hTERT activation, pinealocyte function support, antioxidant enhancement — with the modification primarily impacting pharmacokinetics rather than pharmacodynamics.
This depends on whether the N-terminus of the peptide is directly involved in receptor or molecular target interactions. For most short bioactive peptides, modification of one terminus affects bioactivity only when that terminus is specifically involved in binding — if the core binding interactions are mediated by internal residues, N-terminal modification may have minimal effect on receptor affinity while dramatically improving stability. The available evidence suggests that N-Acetyl Epitalon retains the biological activities of standard Epitalon, implying that the N-terminal modification does not disrupt the key molecular interactions. However, formal receptor binding affinity comparisons (Kd measurements) between the two forms using defined molecular targets are not well represented in the published literature.
This is one of the mechanistically fascinating aspects of Epitalon biology. The most widely proposed mechanism involves epigenetic effects — specifically, the peptide may interact with chromatin-regulatory proteins in a way that alters histone modification patterns at the hTERT promoter, increasing its accessibility for transcription. Short regulatory peptides acting as epigenetic modulators is a well-established concept in Khavinson’s bioregulatory peptide framework, and Epitalon fits this model. The small size of the peptide may actually facilitate nuclear access compared to larger proteins. However, the precise molecular target that Epitalon or N-Acetyl Epitalon physically contacts — the receptor or binding partner that initiates the signaling cascade leading to hTERT promoter activation — has not been definitively characterized and represents an important open question in the field.
The Khavinson research suggests that Epitalon can activate telomerase in near-senescent human cells and allow continued replication beyond the Hayflick limit — indicating that the compound can act on cells whose telomeres are already critically short. Whether this constitutes “reversal” of telomere shortening versus simply preventing further shortening depends on the degree and duration of telomerase activation achieved. Active telomerase would add new TTAGGG repeats to existing telomere ends, and with sufficient duration of activity, telomere length could be meaningfully restored. The research in human fibroblasts showed continued proliferation with maintained (not merely preserved) telomere length, suggesting genuine telomere extension was occurring. The clinical translation of this finding to restoring telomere length in aged human tissues in vivo would require sustained telomerase activity over extended periods — an area where N-Acetyl Epitalon’s improved stability might confer advantage over the parent compound.
Based on the mechanism through which Epitalon influences melatonin — restoring pinealocyte function and normalizing the pineal’s circadian secretory pattern — N-Acetyl Epitalon is expected to have the same effect. The parent compound’s melatonin-normalizing effects in aged animals have been well documented, and since the N-acetylated form works through the same pathways with potentially better delivery, melatonin restoration is an expected property. This is relevant practically: improved melatonin secretion with Epitalon-class compounds may mean that exogenous melatonin supplementation becomes less necessary as a complement if pineal function is being actively supported by the peptide. Some researchers suggest evaluating nocturnal melatonin levels as a biomarker for Epitalon/N-Acetyl Epitalon efficacy.
The longevity evidence for Epitalon comes from multiple model organisms. Studies in Drosophila melanogaster showed increased mean and maximum lifespan with Epitalon treatment. Rodent studies demonstrated reductions in spontaneous tumor incidence — a major mortality cause in aged rodents — and some studies reported modest increases in maximum lifespan. The Khavinson group published clinical follow-up data suggesting reduced all-cause mortality over 6-12 year follow-up periods in elderly subjects who received Epitalon courses compared to controls, though these studies lack the blinding and randomization of contemporary clinical trials. These longevity data are for standard Epitalon; comparable long-duration longevity data for N-Acetyl Epitalon specifically are not yet published at the same scale.
The combination of Epitalon-class compounds with other interventions targeting aging biology is an area of research interest but limited published evidence. The most scientifically coherent combinations target complementary mechanisms — for example, pairing Epitalon (telomere-focused) with compounds targeting mitochondrial function, inflammation, or mTOR signaling, since aging is multi-mechanistic and no single intervention is likely to comprehensively address it. Some research has explored Epitalon in combination with thymalin (a broader thymic extract) based on the original Soviet immunogerontology tradition of using multiple bioregulatory peptides together. Whether N-Acetyl Epitalon specifically produces additive or synergistic effects with other longevity-focused compounds requires dedicated research. Visit our Peptide Database for related anti-aging peptide profiles.
Verification of N-Acetyl Epitalon identity and purity is critical for research use, since the compound is not clinically approved and is manufactured without the quality oversight of pharmaceutical manufacturing. Mass spectrometry (specifically ESI-MS or MALDI-MS) is the gold standard for confirming molecular weight and therefore the presence of the N-acetyl modification — the expected molecular weight of N-Acetyl Epitalon is approximately 472 Da, compared to approximately 430 Da for standard Epitalon, and the 42 Da difference corresponding to the acetyl group should be clearly resolved by mass spectrometry. High-performance liquid chromatography (HPLC) provides purity assessment. Reputable research-grade suppliers should provide certificates of analysis with these verification data. The acetylation should be confirmed specifically rather than assumed, since unacetylated Epitalon incorrectly labeled as the N-acetyl form is a potential quality concern with unregulated peptide manufacturing. Consult our AI Coach for guidance on evaluating research peptide quality documentation.
References
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135(6):590-592. PubMed: 12937682
- Anisimov VN, Khavinson VKh, Provinciali M, et al. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. International Journal of Cancer. 2002;101(1):7-10. PubMed: 12209581
- Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD. Peptide promotes overcoming of the division limit in human somatic cell. Bulletin of Experimental Biology and Medicine. 2004;137(5):503-506. PubMed: 15455139
- Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PubMed: 19904628
- Khavinson VKh, Lezhava TA, Monaselidze JR, et al. Peptide Epitalon activates chromatin at the old age. Neuro Endocrinology Letters. 2003;24(5):329-333. PubMed: 14647006
- Goncharova ND, Khavinson BK, Lapin BA. Regulatory effect of Epithalon on production of melatonin and cortisol in old monkeys. Bulletin of Experimental Biology and Medicine. 2001;131(4):394-396. PubMed: 11550060
- Khavinson V, Diomede F, Miromedov V, et al. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules. 2020;25(3):609. PubMed: 32024112
- Anisimov SV, Khavinson VKh, Anisimov VN. Effect of melatonin and tetrapeptide epitalon on biological age, survival, and spontaneous tumor incidence in male rats. Doklady Biological Sciences. 2004;396:94-97. PubMed: 15384531
- Kossoy G, Zandbank J, Tendler E, et al. Epithalon and colon carcinogenesis: no impact of the tetrapeptide epithalon on aberrant crypt foci and colon tumors incidence in rats treated with 1,2-dimethylhydrazine. Oncology Research. 2003;14(1):39-44. PubMed: 14558577